Effectiveness of Allergen-Specific Immunotherapy in Children with Bronchial Asthma

S.M. Nedelskaya, N.M. Marchuk


The study of clinical and immunological effectiveness of specific allergen vaccination has been carried out among 487 children with bronchial asthma, depending on the duration of treatment, severity of illness and type of vaccinated allergen. It is found that in all cases specific allergen vaccination has anti-inflammatory and immunocorrective action, the effectiveness of specific allergen vaccination reaches 90.32 % in children with mild bronchial asthma and in 96.94 % of children with moderate severity, and the optimal duration of this treatment which is necessary for the formation of stable remission, is 4–5 years.


bronchial asthma; children; clinical and immunological efficacy; specific allergen vaccination


Агеева Е.С. Механизмы программируемой гибели лимфоцитов, эозинофилов и нейтрофилов у больных бронхиальной астмой: Дис... канд. мед. наук. — Томск, 2006. — С. 1-5.

Бойчук С.В. Механизмы апоптоза лимфоцитов периферической крови больных атопической бронхиальной астмой / С.В. Бойчук, И.Г. Мустафин, Р.С. Фассахов // Аллергология. — 2001. — С. 3-7.

Глобальная стратегия лечения и профилактики бронхиальной астмы, пересмотр 2009, 2010 гг.

Дранник Г.Н. Клиническая иммунология и аллергология. — Одесса: Астропринт, 1999. — 603 с.

Емельянов А.В. Специфическая иммунотерапия // Общая аллергология / Под ред. Г.Б. Федосеева. — С.-Пб.: Норд­Мед-Издат, 2001. — Т. 1. — 682-93.

Ласиця О.І., Недельська С.М. Специфічна вакцинація алергенами у дітей: Методичні рекомендації для лікарів-інтернів, лікарів загальної практики та лікарів-алергологів. — 2002. — 44 с.

Bousquet J., Lockey R., Mailing H.J. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper // J. Allergy Clin. Immunol. — 1998. — 102 (Pt. 1). — 558-562.

Calderon M.A., Cox L., Casale T.B., Moingeon P., Demoly P. Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the pub-lished evidence // J. Allergy Clin. Immunol. — 2012. — 129. — 929-934.

European Academy of Allergy and Clinical Immunology.European Declaration on Allergen Immunotherapy. European Academy of Allergy and Clinical Immunology, 2011. Available from:

Szefler S.J., Phillips B.R., Martinez F.D., Chinchilli V.M., Lemanske R.F., Strunk R.C. et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma // J. Allergy Clin. Immunol. — 2005. — 115. — 233-242.

Pajno G.B., Barberio G., De Luca F., Morabito L., Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study // Clin. Exp. Allergy. — 2001. — 31. — 1392-1397.

Penagos M., Passalacqua G., Compalati E., Baena-Cagnani C.E., Orozco S., Pedroza A. et al. Metaanalysis of the efficacy of sublin-gual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age // Chest. — 2008. — 133. — 599-609.

Copyright (c) 2016 CHILD`S HEALTH

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2020


   Seo анализ сайта